A composition for alleviating allergic rhinitis and a method of preparing the same

Abstract

The application discloses a kind of compositions for relieving allergic rhinitis and preparation method thereof, belong to pharmaceutical preparation technical field, the composition includes lavender, green flower white thousand layers, blue glue eucalyptus leaf, Australian eucalyptus leaf, xinyi, turmeric, zedoary, mint, ginseng, radix scrophulariae and radix astragali.Preparation method includes the following steps: proportionally weighed raw material is crushed;Lavender, green flower white thousand layers, blue glue eucalyptus leaf, Australian eucalyptus leaf, xinyi and mint are carried out low-temperature reduced pressure steam distillation, and volatile fraction is collected;Turmeric, zedoary and ginseng are carried out supercritical carbon dioxide extraction, and ethanol aqueous solution is used as entrainer, to obtain supercritical extract;Radix scrophulariae and radix astragali are extracted using ethanol aqueous solution, and concentrated, to obtain polar extract;The volatile fraction, supercritical extract and polar extract are mixed, and are homogenized at low temperature, to obtain the composition, and the composition of the application can be used for preventing and treating allergic rhinitis.

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical formulation technology, specifically, it relates to a composition for relieving allergic rhinitis and its preparation method. Background Technology

[0002] Allergic rhinitis (AR), also known as hay fever, is a chronic, non-infectious inflammatory disease of the nasal mucosa mediated by immunoglobulin E (IgE). Clinically, it mainly manifests as nasal itching, paroxysmal sneezing, clear nasal discharge, and nasal congestion, severely impacting patients' quality of life, sleep, work, and study efficiency. In recent years, with accelerated industrialization, increased air pollution, and changes in lifestyle, the global incidence of allergic rhinitis has shown a significant upward trend. Epidemiological surveys show that the global prevalence of allergic rhinitis is approximately 10%-40%, while the self-reported prevalence in major Chinese cities has reached as high as 17.6%, and it is showing a trend towards affecting younger people, becoming a public health problem that urgently needs to be addressed.

[0003] Currently, clinical medications for allergic rhinitis are mainly classified into the following categories: antihistamines (such as loratadine and cetirizine), glucocorticoids (such as budesonide and fluticasone nasal spray), leukotriene receptor antagonists (such as montelukast), and mast cell stabilizers (such as sodium cromoglycate). While these medications can alleviate symptoms to some extent, they all have limitations. Oral antihistamines can cause central nervous system and anticholinergic adverse reactions such as drowsiness, headache, dry mouth, and blurred vision; long-term use of glucocorticoids may lead to nasal dryness, nosebleeds, pharyngitis, local fungal infections, and may even affect children's growth and development; leukotriene receptor antagonists have the potential risk of inducing neuropsychiatric events. In addition, some patients do not experience significant symptom improvement after treatment with these medications, exhibiting low efficacy or developing drug tolerance, and relapse is common after discontinuation of medication, making long-term stable symptom control difficult to achieve.

[0004] Traditional Chinese medicine and natural plant extracts have a long history of being used to treat allergic rhinitis. Traditional formulas such as Xin Yi San and Cang Er Zi San have certain clinical efficacy. However, traditional Chinese medicine compound formulas have problems such as complex ingredients, unclear mechanisms of action, difficulty in quality control, and hepatotoxicity and nephrotoxicity of some medicinal materials (such as Cang Er Zi), which limit their modern application and promotion.

[0005] In recent years, scholars both domestically and internationally have explored the anti-allergic effects of various natural plant extracts. For example, flavonoids such as quercetin, luteolin, baicalin, and curcumin have been shown to inhibit mast cell degranulation and histamine release. However, single-component formulations often have limited effects and cannot comprehensively counteract the complex pathophysiological processes of allergic rhinitis. Furthermore, existing natural-derived products suffer from drawbacks such as slow onset of action, large fluctuations in efficacy, crude manufacturing processes, and poor stability. In some products, preservatives and fragrances added to the excipients may actually exacerbate allergic reactions.

[0006] Therefore, developing a composition for relieving allergic rhinitis using natural plant extracts as raw materials, with a clear efficacy, no adverse reactions, and long-term safe use, has significant clinical importance and market value. Summary of the Invention

[0007] In order to overcome the problems existing in the prior art, the present invention proposes a composition for relieving allergic rhinitis and a method for preparing the same.

[0008] To achieve the above objectives, the first aspect of the present invention provides a composition for relieving allergic rhinitis, the composition comprising the following components in parts by weight: 10-20 parts lavender, 15-20 parts melaleuca lanceolata, 9-11 parts eucalyptus leaves, 7-9 parts eucalyptus leaves, 10-15 parts magnolia flower, 8-13 parts turmeric, 4-6 parts turmeric, 2-6 parts peppermint, 5-6 parts ginseng, 6-8 parts scutellaria baicalensis, and 5-8 parts astragalus membranaceus.

[0009] Further, the composition comprises the following components in parts by weight: 10 parts lavender, 15 parts melaleuca lanceolata, 9 parts eucalyptus leaves, 7 parts eucalyptus leaves, 10 parts magnolia flower, 8 parts turmeric, 4 parts turmeric, 2 parts peppermint, 5 parts ginseng, 6 parts scutellaria baicalensis, and 5 parts astragalus membranaceus.

[0010] Further, the composition comprises the following components in parts by weight: 20 parts lavender, 20 parts melaleuca lanceolata, 11 parts eucalyptus leaves, 9 parts eucalyptus leaves, 15 parts magnolia flower, 13 parts turmeric, 6 parts turmeric, 6 parts peppermint, 6 parts ginseng, 8 parts scutellaria baicalensis, and 8 parts astragalus membranaceus.

[0011] Further, the composition comprises the following components in parts by weight: 15 parts lavender, 17.5 parts melaleuca lanceolata, 10 parts eucalyptus leaves, 8 parts eucalyptus leaves, 12.5 parts magnolia flower, 10 parts turmeric, 5 parts turmeric rhizome, 4 parts peppermint, 5 parts ginseng, 7 parts scutellaria baicalensis, and 6.5 parts astragalus.

[0012] A second aspect of the present invention provides a method for preparing the composition of the first aspect, comprising the following steps: Each raw material was weighed according to the specified proportions and then pulverized separately. Lavender, Melaleuca odorata, Eucalyptus globulus leaves, Eucalyptus macrocarpa leaves, Magnolia biondii, and peppermint were subjected to low-temperature vacuum steam distillation, and the volatile fractions were collected. Turmeric, Curcuma zedoaria, and ginseng were subjected to supercritical carbon dioxide extraction, with an ethanol-water solution as an entrainer, to obtain a supercritical extract. Scutellaria baicalensis and Astragalus membranaceus were extracted and concentrated with an ethanol-water solution to obtain a polar extract. The volatile fractions, supercritical extract, and polar extract were mixed and homogenized at low temperature to obtain the composition.

[0013] The third aspect of the present invention provides the use of the composition of the first aspect in the preparation of a medicament for the prevention and treatment of allergic rhinitis.

[0014] Through the above technical solution, the present invention can achieve at least the following beneficial effects: The composition of this invention can be used to prevent and treat allergic rhinitis. Detailed Implementation

[0015] Unless otherwise stated, all materials and reagents used in this invention are commercially available.

[0016] In this invention: Lavender refers to the plant *Lavendera*, belonging to the genus *Lavendera* in the family Lamiaceae. Lavandula angustifolia Mill. (Alternative name) Lavandula officinalis dried flower spikes of Chaix; Green-flowered Melaleuca is a plant belonging to the genus Melaleuca in the family Myrtaceae. Melaleuca viridiflora Dried leaves of Sol. ex Gaertn.; Blue gum eucalyptus leaves are from the genus Eucalyptus in the family Myrtaceae. Eucalyptus globulus The dried leaves of Labill. are commonly known as "eucalyptus leaves" in traditional Chinese medicine, and are also called eucalyptus leaves or blue eucalyptus leaves. Australian eucalyptus leaves are from the genus Eucalyptus in the family Myrtaceae. Eucalyptus radiata Dried leaves of Sieber ex DC.

[0017] Magnolia flower, turmeric, turmeric, peppermint, ginseng, scutellaria, and astragalus are the raw materials recorded in Part I of the 2020 edition of the Chinese Pharmacopoeia.

[0018] Example 1 A composition for relieving allergic rhinitis, the composition comprising the following components in parts by weight: 15 parts lavender, 17.5 parts melaleuca lanceolata, 10 parts eucalyptus leaves, 8 parts eucalyptus leaves, 12.5 parts magnolia flower buds, 10 parts turmeric, 5 parts turmeric rhizome, 4 parts peppermint, 5 parts ginseng, 7 parts scutellaria baicalensis, and 6.5 parts astragalus membranaceus.

[0019] The preparation method of the above composition includes the following steps: (1) Weigh out the dry raw materials according to the above mass proportions and grind them to 40 mesh; (2) Mix lavender, green tea tree, blue gum eucalyptus leaves, Australian eucalyptus leaves, magnolia and peppermint powder, add 8 times the amount of distilled water, and steam distill at low temperature and reduced pressure for 2 hours at 60℃ and vacuum degree -0.08MPa. The condensation temperature is controlled at 0-10℃. Collect the volatile fraction for later use. (3) Take turmeric, turmeric and ginseng powder, put them in a supercritical carbon dioxide extraction device, extract pressure 25MPa, extraction temperature 40℃, extraction time 2h, carbon dioxide flow rate to maintain stable extraction; use 70% ethanol aqueous solution as entrainer, the amount of entrainer is 8% of the raw material mass, after extraction, reduce pressure to remove ethanol to obtain supercritical extract. (4) Take Scutellaria baicalensis and Astragalus membranaceus powder, add 8 times the amount of 60% ethanol aqueous solution, extract twice at 65℃ for 1 hour each time, filter, combine the filtrates, concentrate under reduced pressure to a relative density of 1.10-1.20 (60℃) to obtain a polar extract; (5) Mix the volatile fraction obtained in step (2), the supercritical extract obtained in step (3), and the polar extract obtained in step (4), and homogenize at low temperature to obtain the composition for relieving allergic rhinitis.

[0020] Example 2 A composition for relieving allergic rhinitis, the composition comprising the following components in parts by weight: 10 parts lavender, 15 parts melaleuca lanceolata, 9 parts eucalyptus leaves, 7 parts eucalyptus leaves, 10 parts magnolia flower, 8 parts turmeric, 4 parts turmeric rhizome, 2 parts peppermint, 5 parts ginseng, 6 parts scutellaria baicalensis, and 5 parts astragalus membranaceus.

[0021] The preparation method of the above composition includes the following steps: (1) Weigh out the dry materials according to the above mass proportions and grind them to 20 mesh; (2) Mix lavender, green tea tree, blue gum eucalyptus leaves, Australian eucalyptus leaves, magnolia and peppermint powder, add 8 times the amount of distilled water, and steam distill at low temperature and reduced pressure for 2 hours at 55℃ and vacuum degree -0.07MPa. The condensation temperature is controlled at 0-10℃. Collect the volatile fraction for later use. (3) Take turmeric, turmeric and ginseng powder, put them in a supercritical carbon dioxide extraction device, extract pressure 25MPa, extraction temperature 40℃, extraction time 2h, carbon dioxide flow rate to maintain stable extraction; use 70% ethanol aqueous solution as entrainer, the amount of entrainer is 8% of the raw material mass, after extraction, reduce pressure to remove ethanol to obtain supercritical extract. (4) Take Scutellaria baicalensis and Astragalus membranaceus powder, add 8 times the amount of 60% ethanol aqueous solution, extract twice at 65℃ for 1 hour each time, filter, combine the filtrates, concentrate under reduced pressure to a relative density of 1.10-1.20 (60℃) to obtain a polar extract; (5) Mix the volatile fraction obtained in step (2), the supercritical extract obtained in step (3), and the polar extract obtained in step (4), and homogenize at low temperature to obtain the composition for relieving allergic rhinitis.

[0022] Example 3 A composition for relieving allergic rhinitis, the composition comprising the following components in parts by weight: 20 parts lavender, 20 parts melaleuca lanceolata, 11 parts eucalyptus leaves, 9 parts eucalyptus leaves, 15 parts magnolia flower, 13 parts turmeric, 6 parts turmeric, 6 parts peppermint, 6 parts ginseng, 8 parts scutellaria baicalensis, and 8 parts astragalus membranaceus.

[0023] The preparation method of the above composition includes the following steps: (1) Weigh out the dry materials according to the above mass fractions and grind them to 60 mesh; (2) Mix lavender, green tea tree, blue gum eucalyptus leaves, Australian eucalyptus leaves, magnolia and peppermint powder, add 8 times the amount of distilled water, and steam distill at low temperature and reduced pressure for 2 hours at 65℃ and vacuum degree -0.09MPa. The condensation temperature is controlled at 0-10℃. Collect the volatile fraction for later use. (3) Take 13 parts of turmeric, 6 parts of turmeric and 6 parts of ginseng, place them in a supercritical carbon dioxide extraction device, extract pressure 25 MPa, extraction temperature 40℃, extraction time 2h, carbon dioxide flow rate to maintain stable extraction; use 70% ethanol aqueous solution as entrainer, the amount of entrainer is 8% of the raw material mass, after extraction, reduce pressure to remove ethanol to obtain supercritical extract. (4) Take 8 parts of Scutellaria baicalensis and 8 parts of Astragalus membranaceus, add 8 times the amount of 60% ethanol aqueous solution, extract twice at 65℃ for 1 hour each time, filter, combine the filtrates, and concentrate under reduced pressure to a relative density of 1.10-1.20 (60℃) to obtain a polar extract; (5) Mix the volatile fraction obtained in step (2), the supercritical extract obtained in step (3), and the polar extract obtained in step (4), and homogenize at low temperature to obtain the composition for relieving allergic rhinitis.

[0024] Comparative Example 1 The difference between Comparative Example 1 and Example 1 is that Magnolia biondii is replaced with Ophiopogon japonicus.

[0025] Comparative Example 2 The difference between Comparative Example 2 and Example 1 is that turmeric and turmeric are replaced with equal parts by mass of scutellaria and astragalus, while the other raw material parts by mass and preparation methods are the same as in Example 1.

[0026] Comparative Example 3 The difference between Comparative Example 3 and Example 1 is that the low-temperature reduced pressure steam distillation and supercritical carbon dioxide fractional extraction process are not used. Instead, all raw materials are mixed according to the mass fraction of Example 1, and 10 times the amount of distilled water is added. The mixture is boiled and extracted twice, 1 hour each time. The filtrates are combined to obtain the composition.

[0027] Experimental Case Clinical Efficacy Experiment I. Subject Screening: 1.1 Subject inclusion criteria: 150 subjects who simultaneously met all of the following criteria were selected and divided into six groups of 25 each, and were given the drug compositions of Examples 1 to 3 and Comparative Examples 1 to 3, respectively: Age: 18-65 years old (inclusive), gender not limited; Diagnosis: Meets the diagnostic criteria for allergic rhinitis (AR) in the "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022 Revised Edition)"; Symptom score: TNSS score ≥ 6 (out of 12) during the screening period; Disease duration: ≥6 months, with a clear history of allergic rhinitis; Compliance: Students understand the research protocol, are willing to sign the informed consent form, and cooperate with follow-up visits; Able to use nebulizers correctly; 1.2 Exclusion Criteria: Subjects meeting any of the following criteria will be excluded: Disease related: Structural abnormalities such as severe nasal septum deviation, nasal polyps, and nasal tumors. Acute sinusitis, acute upper respiratory tract infection (must be cured for 2 weeks before enrollment). Asthma during an attack or asthma requiring systemic glucocorticoid therapy Other allergic diseases requiring systemic treatment Medication-related: Patients who had used nasal corticosteroids within 2 weeks prior to enrollment; Those who used antihistamines or leukotriene receptor antagonists within one week prior to enrollment; Patients who had used systemic glucocorticoids within 4 weeks prior to enrollment; Currently undergoing desensitization therapy or having undergone desensitization therapy within 6 months prior to enrollment; Allergic to any component of the investigational drug; Overall condition: Severe heart, liver, kidney, and hematological diseases; Pregnant or breastfeeding women; Mental illness or cognitive impairment that prevents cooperation in research; other: Have participated in other clinical studies in the past 3 months; Other circumstances where the researchers deem it unsuitable for participation in this study; II. Dosing Regimen 2.1 Dosing regimen Route of administration: Nasal inhalation (nasal inhaler); Dosage: 3-5 puffs each time (approximately 0.1 ml of pure extract); Frequency: 4 times a day (morning, noon, evening, and before bed); Treatment duration: 4 consecutive weeks; 2.2 Regulations for Combined Drug Use Permitted: Physiological nasal irrigation with saline solution; Prohibited: Other anti-allergy medications and hormonal medications (unless used to treat comorbidities); Emergency medication: Antihistamines may be used for a short period of time in cases of severe symptoms (detailed records required); 2.3 Drug Preservation and Dispensing Storage conditions: Room temperature (15-25℃), away from light, avoid freezing; Validity period: 1 month; Distribution Management: Designated personnel are responsible for registering and distributing medications, collecting any remaining medications during each visit, and calculating adherence.

[0028] III. Research Process and Observation Indicators 3.1 Research Process Screening period (-7 to 0 days) → Baseline (0 days) → Treatment period (1-4 weeks) → Follow-up period (5-8 weeks) V1 Screening → V2 Baseline → V3 (2 weeks) → V4 (4 weeks of treatment) → V5 (6 weeks) → V6 (8 weeks of study) 3.2 Detailed table of each visit (Table 1) Table 1. Detailed list of each visit content

[0029] Note: TNSS = Total Nasal Symptom Score; VAS = Visual Analogue Scale; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; PNIF = Peak Nasal Inspiratory Flow Rate; 3.3 Main therapeutic indicators and evaluation methods This study used the total nasal symptom score (TNSS) and the visual analogue scale (VAS) to evaluate the improvement of allergic rhinitis symptoms in each group of subjects. TNSS served as the primary efficacy indicator, evaluating specific nasal symptoms such as nasal congestion, runny nose, nasal itching, and sneezing; VAS served as a secondary efficacy indicator, evaluating subjects' subjective perception of the overall severity of symptoms. The baseline visit at V2 was used as the baseline for efficacy evaluation, and the final visit at V6 was used as the primary efficacy evaluation point. The symptom improvement process was also evaluated in conjunction with the follow-up results at V3, V4, and V5.

[0030] score The TNSS (Total Nasal Disorder Score) is calculated by adding the scores of four symptoms: nasal congestion, runny nose, nasal itching, and sneezing. Each symptom is scored from 0 to 3 points according to its severity, and the total TNSS score ranges from 0 to 12 points. The lower the score, the milder the nasal symptoms. The scoring criteria for each TNSS symptom are shown in Table 2.

[0031] Table 2 TNSS Individual Symptom Scoring Criteria

[0032] TNSS decrease value = TNSS at V2 - TNSS at V6 TNSS improvement rate = (TNSS at V2 - TNSS at V6) / TNSS at V2 × 100% The efficacy evaluation was categorized based on the TNSS improvement rate: a TNSS improvement rate ≥ 66% was considered significantly effective; 25% < TNSS improvement rate < 66% was considered effective; and a TNSS improvement rate ≤ 25% was considered ineffective. The overall effective rate was calculated as: (Number of significantly effective cases + Number of effective cases) / Number of cases evaluated for efficacy × 100%.

[0033] score Participants used a visual analog scale (VAS) ranging from 0 to 10 to assess the overall severity of allergic rhinitis symptoms. A score of 0 indicated no symptoms, and a score of 10 indicated the most severe symptoms the participant could imagine. Lower scores indicated milder subjective overall symptoms. The VAS scoring criteria are shown in Table 3. The raw scores of 0 to 10 were used for statistical analysis.

[0034] Table 3 VAS Scoring Criteria

[0035] VAS decrease value = VAS at V2 - VAS at V6 3.3.3 Data aggregation method TNSS and VAS scores are expressed as mean ± standard deviation. The efficacy of each group is summarized using V2 and V6 scores and their decreases; the efficacy trend is also verified by considering changes in V3–V6 visit scores. The number of subjects with effective V6 scores is used to evaluate the efficacy of TNSS classification. The overall evaluation is primarily based on the decrease in TNSS score and the total TNSS effective rate, combined with the decrease in VAS score to assess the overall symptom improvement of the subjects.

[0036] IV. Test Results 4.1 Participant completion status This trial included a total of 150 participants, with 25 participants each in Example 1, Example 2, Example 3, Comparative Example 1, Comparative Example 2, and Comparative Example 3. During the V6 visit, 125 participants had valid TNSS and VAS scores, including 22 in Example 1, 21 in Example 2, 22 in Example 3, 23 in Comparative Example 1, 18 in Comparative Example 2, and 19 in Comparative Example 3. 144, 138, and 132 participants had valid scores in V3, V4, and V5, respectively.

[0037] 4.2 Summary of therapeutic effects Table 4 summarizes the TNSS, VAS scores and improvement status for each group at baseline (V2) and visit (V6). For ease of comparison, the TNSS and VAS columns are listed in the format of "V2 baseline score → V6 score".

[0038] Table 4 Summary of TNSS and VAS efficacy results for each group

[0039] Note: Scoring data are expressed as mean ± standard deviation; V2 scores use data from the same batch of subjects matched with the corresponding valid V6 scores. The overall TNSS effectiveness is calculated using subjects with valid V6 scores as the denominator.

[0040] The results showed that the TNSS and VAS scores of Examples 1, 2, and 3 were significantly lower than the baseline at V2, and the overall decrease in TNSS and VAS was greater than that of each pair, indicating that the composition described in this invention can effectively improve nasal congestion, runny nose, nasal itching, sneezing, and the subjects' overall subjective symptoms. Follow-up results from V3 to V6 showed that the symptom scores of each example group gradually decreased after treatment and maintained a good level of improvement in subsequent visits, consistent with the summary results of efficacy from V2 to V6.

[0041] 4.3 Evaluation of the efficacy of each embodiment Example 1 showed the highest TNSS reduction score of 4.82, and the highest overall TNSS efficacy rate of 86.36%. Its VAS reduction score of 4.32 indicated significant improvement in both nasal symptoms and overall subjective symptoms. Considering both the primary TNSS efficacy index and the secondary VAS efficacy index, Example 1 demonstrated the best overall efficacy, indicating that the raw material ratio used in Example 1 has a good synergistic effect and can be considered a preferred ratio for this invention.

[0042] In Example 3, the TNSS score decreased by 4.73, similar to that of Example 1; the VAS score decreased by 4.36, the highest among all groups, indicating a significant improvement effect on nasal and overall symptoms. However, its overall efficacy was second only to Example 1. In Example 2, the TNSS score decreased by 3.90, the VAS score decreased by 3.57, and the total effective rate of TNSS was 80.95%, also demonstrating good symptom improvement. Based on all indicators, the efficacy ranking of the examples is: Example 1, Example 3, Example 2.

[0043] Compared with the comparative examples, the three embodiments showed better overall performance in terms of TNSS reduction value, VAS reduction value and TNSS total effectiveness, indicating that the raw materials of the present invention can exert a synergistic effect after being combined according to the above-described proportions, thereby improving the overall improvement effect on allergic rhinitis symptoms.

[0044] V. Conclusion The results of this experiment show that the compositions described in Examples 1, 2 and 3 can effectively reduce the TNSS and VAS scores of subjects with allergic rhinitis, and have a good effect on improving nasal congestion, runny nose, nasal itching, sneezing and the overall symptoms of the subjects. Their overall efficacy is better than that of each pair.

[0045] Among them, Example 1 showed the largest decrease in TNSS and the highest overall TNSS efficacy, and the VAS score also improved significantly, indicating that the raw material ratio used in Example 1 could produce a good comprehensive synergistic effect, and its overall therapeutic effect was the best. Example 3 also showed significant improvement in TNSS and VAS, but its overall therapeutic effect was second only to Example 1; Example 2 also had a good symptom improvement effect.

[0046] The above results demonstrate that the composition of the present invention has a definite effect in improving the symptoms of allergic rhinitis, and the formulation described in Example 1 has the best overall therapeutic effect and can be used as a preferred embodiment of the present invention.

Claims

1. A composition for relieving allergic rhinitis, characterized in that: The composition comprises the following components in parts by weight: 10-20 parts lavender, 15-20 parts melaleuca lanceolata, 9-11 parts eucalyptus leaves, 7-9 parts eucalyptus leaves, 10-15 parts magnolia flower, 8-13 parts turmeric, 4-6 parts turmeric, 2-6 parts peppermint, 5-6 parts ginseng, 6-8 parts scutellaria baicalensis, and 5-8 parts astragalus membranaceus.

2. The composition for relieving allergic rhinitis according to claim 1, characterized in that: The composition comprises the following components in parts by weight: 10 parts lavender, 15 parts melaleuca lanceolata, 9 parts eucalyptus leaves, 7 parts eucalyptus leaves, 10 parts magnolia flower, 8 parts turmeric, 4 parts turmeric, 2 parts peppermint, 5 parts ginseng, 6 parts scutellaria baicalensis, and 5 parts astragalus membranaceus.

3. The composition for relieving allergic rhinitis according to claim 1, characterized in that: The composition comprises the following components in parts by weight: 20 parts lavender, 20 parts melaleuca lanceolata, 11 parts eucalyptus leaves, 9 parts eucalyptus leaves, 15 parts magnolia flower, 13 parts turmeric, 6 parts turmeric, 6 parts peppermint, 6 parts ginseng, 8 parts scutellaria baicalensis, and 8 parts astragalus membranaceus.

4. The composition for relieving allergic rhinitis according to claim 1, characterized in that: The composition comprises the following components in parts by weight: 15 parts lavender, 17.5 parts melaleuca lanceolata, 10 parts eucalyptus leaves, 8 parts eucalyptus leaves, 12.5 parts magnolia flower, 10 parts turmeric, 5 parts turmeric, 4 parts peppermint, 5 parts ginseng, 7 parts scutellaria baicalensis, and 6.5 parts astragalus membranaceus.

5. A method for preparing the composition according to any one of claims 1-4, characterized in that: The process includes the following steps: weighing each raw material according to the specified proportions and then pulverizing them separately; performing low-temperature vacuum steam distillation on lavender, melaleuca lanceolata, eucalyptus leaves, eucalyptus leaves, magnolia buds, and peppermint, and collecting the volatile fractions; performing supercritical carbon dioxide extraction on turmeric, turmeric rhizome, and ginseng, using an ethanol-water solution as an entrainer to obtain the supercritical extract; and extracting and concentrating scutellaria baicalensis and astragalus membranaceus using an ethanol-water solution to obtain the polar extract. The volatile fraction, supercritical extract, and polar extract are mixed and homogenized at low temperature to obtain the composition.

6. The use of the composition according to any one of claims 1-4 in the preparation of a medicament for the prevention and treatment of allergic rhinitis.

Images